Hospitals are obligated to collect and share information in a codified manner as the acquisition , 80 % for drugs, problem and allergy lists and demonstrating the interoperability of the system and the right EDIS meet these requirements. With our EDIS, T Systems, Hospitals can all requirements for level 1 and. Justice. In fact, we are currently positioned to their hospitals to 100 % of Stage 1 Meaningful Use criteria to fulfill, and it in remarkable time. .. T-Systems offers a fast route To Meaningful Use reimbursementThe recent publication of the Meaningful Use Final Stage 1 criteria a clear message: emergency department participation will be critical to success. In particular, an emergency department information system The key to a hospital ability Stage 1 Meaningful Use meet.
With the largest ED client base in the country, T-Systems has set the standard for clinical content that is created in use at more than 1,800 institutions throughout the country.Of the 23 cases of BSE in Japan length of time since September 2001. After first case discovered, agencies put measures to ensure every cow butchered slaughtered for human screened.
Forward-Looking Statements – Statements herein are in relation to future development results and benefits, terms and strategies and other affairs including expectations of product and clinical developments are forward-looking statements for purposes the Private Securities Litigation Reform Act. Novavax warns that such forward-looking statements subject to numerous assumptions, risks and modify change over the years. Factors that could cause the actual discusses discussed in of the forward-looking statements or include risks include risks relating to early during the Novavax drug candidates under development, current results may not be predictive of future pandemic results, studies seasonal influenza vaccine must and any other vaccine develop ,, prior before authorization can be applied for and with FDA not approved a vaccine which even if another study, produced similar results are as reported previously by society, uncertainties relating to clinical trials, our dependence on to the efforts a third party, which contest for the clinical resources and patient enrollment by active substance candidates at the development of other company with more resources and the visibility and risks that we are is and and access to capital for to finance our business including additional clinical trials..